Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study

Conclusion:
Single-dose MP intake met all noninferiority efficacy and safety outcome measures in comparison to dispersible levodopa/benserazide. Clinical effects of high-dose MP were similar to levodopa alone at the same dose, with a more favorable tolerability profile.

ClinicalTrials.gov identifier:
NCT02680977.

Source: Neurology - July 31, 2017 Category: Neurology Authors: Cilia, R., Laguna, J., Cassani, E., Cereda, E., Pozzi, N. G., Isaias, I. U., Contin, M., Barichella, M., Pezzoli, G. Tags: Parkinson's disease/Parkinsonism, Clinical trials Randomized controlled (CONSORT agreement), Class II ARTICLE Source Type: research